Swipe om te navigeren naar een ander artikel
The online version of this article (https://doi.org/10.1007/s11136-019-02148-2) contains supplementary material, which is available to authorized users.
The original version of this article was revised due to the retrospective open access order.
A complete list of study group investigators is included in electronic supplementary material.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints.
Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26.
At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients.
Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures.
Trial ID Registration: NCT01997229, NCT02301624.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Supplementary material 1 (DOCX 34 KB)11136_2019_2148_MOESM1_ESM.docx
Conti-Fine, B. M., Milani, M., & Kaminski, H. J. (2006). Myasthenia gravis: Past, present, and future. Journal of Clinical Investigation, 116(11), 2843–2854. CrossRef
Howard, J. F. Jr. (2018). Myasthenia gravis: The role of complement at the neuromuscular junction. Annals of the New York Academy of Sciences, 1412(1), 113–128. CrossRef
Elsais, A., Wyller, V. B., Loge, J. H., & Kerty, E. (2013). Fatigue in myasthenia gravis: Is it more than muscular weakness? BMC Neurology, 13, 132. CrossRef
Paul, R. H., Cohen, R. A., Goldstein, J. M., & Gilchrist, J. M. (2000). Fatigue and its impact on patients with myasthenia gravis. Muscle & Nerve, 23(9), 1402–1406. CrossRef
Symonette, C. J., Watson, B. V., Koopman, W. J., Nicolle, M. W., & Doherty, T. J. (2010). Muscle strength and fatigue in patients with generalized myasthenia gravis. Muscle & Nerve, 41(3), 362–369. CrossRef
Hoffmann, S., Ramm, J., Grittner, U., Kohler, S., Siedler, J., & Meisel, A. (2016). Fatigue in myasthenia gravis: Risk factors and impact on quality of life. Brain and Behavior. 6(10), e00538. CrossRef
Tran, C., Bril, V., Katzberg, H. D., & Barnett, C. (2018). Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle & Nerve, 58(2), 197–203. CrossRef
Muppidi, S. (2012). The myasthenia gravis-specific activities of daily living profile. Annals of the New York Academy of Sciences, 1274, 114–119. CrossRef
Barohn, R. J., McIntire, D., Herbelin, L., Wolfe, G. I., Nations, S., & Bryan, W. W. (1998). Reliability testing of the quantitative myasthenia gravis score. Annals of the New York Academy of Sciences, 841, 769–772. CrossRef
Burns, T. M., Grouse, C. K., Conaway, M. R., & Sanders, D. B. (2010). Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle & Nerve, 41(2), 219–226.
Cella, D., Lai, J. S., Nowinski, C. J., Victorson, D., Peterman, A., Miller, D., et al. (2012). Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology. Neurology, 78(23), 1860–1867. CrossRef
Miller, D. M., Bethoux, F., Victorson, D., Nowinski, C. J., Buono, S., Lai, J. S., et al. (2016). Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis. Multiple Sclerosis, 22(6), 830–841. CrossRef
Victorson, D., Cavazos, J. E., Holmes, G. L., Reder, A. T., Wojna, V., Nowinski, C., et al. (2014). Validity of the neurology quality-of-life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy & Behavior, 31, 77–84. CrossRef
Nowinski, C. J., Siderowf, A., Simuni, T., Wortman, C., Moy, C., & Cella, D. (2016). Neuro-QoL health-related quality of life measurement system: Validation in Parkinson’s disease. Movement Disorders, 31(5), 725–733. CrossRef
National Institute of Neurological Disorders (NINDS). User manual for the quality of life in neurological disorders (Neuro-QoL) measures, version 2.0. March 2015. Accessed June 14, 2018, from http://www.healthmeasures.net/images/neuro_qol/Neuro-QOL_User_Manual_v2_24Mar2015.pdf.
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology, 25(11), 1256–1264. CrossRef
Howard, J. F. Jr., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., et al. (2017). Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, 16(12), 976–986. CrossRef
ECU-MG-302: An extension trial of ECU-MG-301 to evaluate safety and efficacy of eculizumab in refractory generalized myasthenia gravis. Accessed July 2, 2018, from http://clinicaltrials.gov/ct/show/NCT02301624.
Gao, X., Schwartz, T. A., Preisser, J. S., & Perin, J. (2017). GEEORD: A SAS macro for analyzing ordinal response variables with repeated measures through proportional odds, partial proportional odds, or non-proportional odds models. Computer Methods and Programs in Biomedicine, 150, 23–30. CrossRef
Swinscow, T. D. V. (1997). Statistics at square one, ninth edition. London: BMJ Publishing Group.
Kluger, B. M., Krupp, L. B., & Enoka, R. M. (2013). Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy. Neurology, 80(4), 409–416. CrossRef
Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., et al. (2019). Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & Nerve. https://doi.org/10.1002/mus.26447.
- Eculizumab improves fatigue in refractory generalized myasthenia gravis
Jing Jing Wang
James F. Howard Jr.
The REGAIN Study Group
- Springer International Publishing
Quality of Life Research
An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation - An Official Journal of the International Society of Quality of Life Research
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649